
When Science Isn’t Enough: Breaking Barriers to Care in Rare Disease
What happens when scientific progress outpaces patients’ real-world experiences? For people living with rare diseases, scientific innovation alone doesn't guarantee access to care. The journey from diagnosis to treatment can be filled with obstacles, and patient advocacy organizations play a critical role in closing these gaps. In this episode, host Eric Racine and co-host Allie Boutin of Sanofi have an insightful conversation with Aviva Rosenberg, CEO and Co-Founder of the Gaucher Community Alliance. They explore what patient advocates can do to address barriers to diagnosis, treatment access, and care. As someone living with Gaucher disease, the mother of a son with the same condition, and a healthcare attorney, Aviva brings a unique perspective on the challenges patients face and how advocacy can help overcome them. Drawing on her nearly 20-year journey to diagnosis and her leadership in the rare disease community, Aviva shares how she turns lived experience into actions for newborn screening advocacy, policy change, patient education, and community building, and why patient voices must be included early in healthcare innovation to develop solutions that address their real needs. In this episode, you'll learn: What advocacy organizations can do to help patients and families navigate a complex healthcare system to access the treatments and care they need How policy advocacy can address systemic barriers, from newborn screening and insurance restrictions to treatment affordability and access to home infusions Ways to empower patients and families through education, peer connections, and grassroots advocacy that strengthens communities How patient advocacy organizations can partner with researchers and industry to shape innovation priorities and help accelerate development of treatments that matter most to patients This episode offers actionable insights for patient advocates and healthcare professionals looking to close the divide between scientific progress and a better patient experience. It's a powerful reminder that scientific breakthroughs only fulfill their promise when patients can benefit from them, and that strong advocacy can help bridge the gap between innovation and access.















